The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback